Caffeic acid derivatives for anti-angiogenesis
US11066378B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 4, 2015 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Jun 4, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention develops a series of methyl caffeate derivatives having biological activity in anti-angiogenesis. The present invention suggests that the compounds of the invention possess inhibiting angiogenesis through regulation of VEGF/VEGFR-2 and its downstream signaling cascades in the vascular endothelial cells (VECs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.